Guidance particularly addresses the value of ultrasound in patient-provider shared decision-making in management of care.

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

Even if you've been diagnosed with RA, your healthcare provider may want to investigate other possible causes if you are not ...

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

Arthritis is a common acute or chronic condition affecting the joints and surrounding tissues. It’s estimated that roughly 18 ...

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid ... which ...

Limited data exist on psoriatic arthritis (PsA) treatment in lower-income regions, particularly from the patient perspective. This study explores the challenges faced by socioeconomically vulnerable ...

(Photo Credit: Moment RF/Getty Images) Biologics can treat a variety of conditions, such as cancer, psoriasis, rheumatoid arthritis (RA ... life or if you have severe symptoms.

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.